Deprenyl compounds for treatment of glaucoma

• US 5,981,598 A
• Filed: 07/20/1998
• Issued: 11/09/1999
• Est. Priority Date: 02/10/1995
• Status: Expired due to Fees

• Current Assignee: The Governing Council of the University of Toronto (University of Toronto)
• Original Assignee: University of Toronto Innovations Foundation
• Inventors: Tatton, William G.
• Primary Examiner(s): FAY, ZOHREH A
• Application Number:
  US09/119,337
• Time in Patent Office: 477 Days
• Field of Search: 514/649, 514/654, 514/913
• US Class Current: 514/649
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics

Abstract

Methods and kits for treament of glaucoma are disclosed. In general, the methods of the invention include administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.

Claims

1. A method for treating a subject for glaucoma, comprising:

administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.

2. The method of claim 1, wherein the deprenyl compound is represented by the structure:

##STR12## in which R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

R₂ is hydrogen or alkyl;

R₃ is a single bond, alkylene, or --(CH₂)_n--X--(CH₂)_m ;

in which X is O, S, or N-methyl;

m is 1 or 2; and

n is 0,1, or 2;

R₄ is alkyl, alkenyl, alkynyl, heterocyclyl, aryl or aralkyl; and

R₅ is alkylene, alkenylene, alkynylene and alkoxylene; and

R₆ is C₃ -C₆ cycloalkyl or

space="preserve" listing-type="equation">--C.tbd.CH;

or

R₂ and R₄ --R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

3. The method of claim 2, wherein R₁ is a group that can be removed in vivo.

4. The method of claim 2, wherein R₁ is hydrogen.

5. The method of claim 2, wherein R₁ is alkyl.

6. The method of claim 5, wherein R₁ is methyl.

7. The method of claim 2, wherein R₂ is methyl.

8. The method of claim 2, wherein R₃ is methylene.

9. The method of claim 2, wherein R₄ is aryl.

10. The method of claim 2, wherein R₄ is phenyl.

11. The method of claim 2, wherein R₅ is methylene.

12. The method of claim 2, wherein R₆ is

13. The method of claim 2, wherein the deprenyl compound has the structure ##STR13## wherein R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl.

14. The method of claim 1, wherein the deprenyl compound is (-)-deprenyl.

15. The method of claim 1, wherein the deprenyl compound is (-)-pargyline.

16. The method of claim 1, wherein the deprenyl compound is (-)-desmethyldeprenyl.